Management
Thomas Reynolds
Tom Reynolds is the President of NEXT Molecular Analytics. In his previous professional positions, Reynolds was a co-founder of Commonwealth Biotechnologies, Inc, the predecessor company to NEXT Molecular Analytics, founded in 1992, and continuously served as its Executive Vice President, Director, and Secretary. Reynolds helped take CBI public in 1997, with an IPO and listing on NASDAQ. In 2009 Reynolds and Dr. Harris spun out US based operations of CBI into a private company, AIBioTech, LLC. Expertise in routine clinical testing, molecular diagnostics and genetics, infectious disease testing, next generation sequencing and personal medicine related technologies. Subject matter expert in molecular diagnostic assay development biodefense/bio-crime and human DNA forensics areas. From 1987 until 1997, Reynolds was in the Department of Microbiology Biology and Immunology at Virginia Commonwealth University where he served as Manager of the Nucleic Acids Core Laboratory as part of the Massey Cancer Center. Reynolds is a co-inventor of US patents, and co-author of more than 45 peer reviewed journal articles and book chapters, in the research area of molecular genetics.
​
Robert B. Harris, Ph.D
Dr. Harris is the current Chief Financial Officer and Chief Scientific Officer of NEXT Molecular Analytics. In his previous professional positions, Harris was a co-founder of Commonwealth Biotechnologies, Inc, the predecessor company to NEXT Molecular Analytics, founded in 1992, and continuously served as its President, Director, and CEO. Then, Harris served as President and CSO of American International Biotechnology LLC. Until 1997, Dr. Harris was employed in the Department of Biochemistry and Molecular Biophysics at Virginia Commonwealth University, rising through the academic ranks to full Professor. Dr. Harris received a joint Bachelor’s degree in Chemistry and Biology from the University of Rochester, Rochester, NY, and the Master’s and Doctoral degrees from New York University, in Biochemistry and Biophysical Chemistry. Dr. Harris is the co-author of more than 75 peer reviewed journal articles and book chapters, mostly in areas of his research expertise: the role of macromolecular structure in biological function. Dr. Harris is a former Established Investigator of the American Heart Association, and is co-inventor of US and foreign patents.
​
Management
Gregory Meyers
Mr. Meyers is currently the Chief Operating Officer (COO) of NEXTMolecular Analytics. Previously, he was Vice President of DNA Services at American International Biotechnology, LLC., in Richmond, VA. He was responsible for oversight and direction of, among other labs, the clinical molecular diagnostic lab where he designed and led the development and validation of several next generation sequencing diagnostic assays used for clinical practice. Prior to that, he served as a Senior Systems Analyst for Analytic Services, Inc. (ANSER), providing advisory and assistance service support to the Department of Defense Transformational Medical Technologies program, serving as a subject matter expert focused mainly on the areas of pathogen identification and characterization and bioinformatics. Prior to joining ANSER, Mr. Meyers was a Group Leader, DNA Services, Commonwealth Biotechnologies, Inc., where he oversaw laboratory operations and scientific program direction of molecular biology, DNA sequencing, and microbial forensic and diagnostic service areas, and Project Manager, Icoria, Inc. where he was responsible for all project management aspects of $55million agricultural genomics collaboration between Monsanto Inc. and Icoria. Mr. Meyers received his BS degree from Virginia Tech in Biology, with an emphasis on microbiology, and his MS degree from VCU/MCV in Microbiology and Immunology. Mr. Meyers is the author of numerous peer reviewed publications and is a co-inventor on several US patents.
​
Dai Li, MD, PhD
Dai “Dave” Li MD, MSc. PhD is the current Chief Medical Officer and Laboratory Director of NEXT Molecular Analytics. Dr. Li brings to NEXT Molecular Analytics over two decades of experience in health and clinical sciences. He obtained his MB/MD at the Sun Yat-Sen University School of Medicine and Cancer Center in Guangzhou, China, and his MSc/PhD from the University of Texas M.D. Anderson Cancer Center. He received additional training in tumor immunology from the Department of Surgery and Organ Transplantation at the University of Texas Health Science Center in Houston, as well as in Clinical Informatics from the Department of Health Informatics at The Johns Hopkins University School of Medicine in Baltimore, Maryland.
​
He completed a combined residency in medical oncology and laboratory medicine at the Sun Yat-sen University Cancer Center. Subsequently, he did clinical fellowships in Clinical Pathology at the University of Texas Southwestern Medical Center, Parkland Memorial Hospital, and at The Johns Hopkins Medical Institutions. Dr. Li then accepted a faculty position of pathology at the Johns Hopkins Medical Institutions with the Division of Clinical Pathology. In 1999 he became the Manager of Clinical Development, and Medical Director of Wako Clinical Laboratory of Wako Chemicals, USA, Inc., a subsidiary of Wako Pure Chemical Industries, Ltd and Takeda Pharmaceutical Company Ltd of Osaka, Japan. In 2004, he was recruited as a Medical Officer for the US/HHS Food and Drug Administration (FDA), Office of Device Safety and In Vitro Diagnostics in Rockville, Maryland. In 2010, he became the Chief Medical Officer at Wako Life Sciences, Inc. in charge of medical and regulatory affairs. In 2013, he assumed a position of Director of Clinical Informatics with Health Diagnostic Laboratory, Inc.
​
Dr. Li is a physician certified by the American Medical Association (AMA) and the United States National Board of Medical Examiners/ECFMG. He is also certified by College of American Pathologists (CAP) and Center for Medicare and Medicaid Services (CMS/CLIA) as a clinical laboratory director.
​
Dr. Li’s interest includes precision medicine, oncology biomarkers, cancer targeted therapy, biomedical and clinical informatics.
​